Xue Yang, Maisel Alan, Peacock W Frank
Division of Cardiology, University of California San Diego, La Jolla, CA, USA.
Future Cardiol. 2014 Mar;10(2):221-7. doi: 10.2217/fca.14.9.
Increasing attention is being paid towards reducing short-term heart failure readmissions in recent years. Biomarkers such as galectin-3 are likely to play pivotal roles in future heart failure management strategies as they can provide objective information on various pathophysiologic processes involved in heart failure. Galectin-3 is a biomarker of inflammation and fibrosis, which is strongly associated with adverse remodeling of the myocardium and subsequent left ventricular dysfunction. Clinically, elevated galectin-3 levels are associated with increased risk for short- and long-term risk for mortality and heart failure readmission. Galectin-3 can provide incremental predictive value for adverse events over natriuretic peptides. Although significant work is still required to further define the role of galectin-3, it has the potential to become an important part of future heart failure management algorithms by helping to provide an individualized risk profile, which can be used to optimize resource allocation and improve treatment outcomes.
近年来，人们越来越关注减少短期心力衰竭再入院情况。像半乳糖凝集素-3这样的生物标志物在未来心力衰竭管理策略中可能发挥关键作用，因为它们可以提供有关心力衰竭所涉及的各种病理生理过程的客观信息。半乳糖凝集素-3是一种炎症和纤维化的生物标志物，与心肌不良重塑及随后的左心室功能障碍密切相关。临床上，半乳糖凝集素-3水平升高与短期和长期死亡风险及心力衰竭再入院风险增加相关。与利钠肽相比 ，半乳糖凝集素-3可为不良事件提供额外的预测价值。尽管仍需要大量工作来进一步明确半乳糖凝集素-3的作用，但它有潜力通过帮助提供个性化风险概况，成为未来心力衰竭管理算法的重要组成部分，这可用于优化资源分配并改善治疗结果。
